Neuralstem (CUR) 4.66 $CUR
Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference
PR Newswire - Mon Apr 07, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) will present Phase I data at the Keystone Symposia, "Engineering Cell Fate and Function," in Olympic Valley, California, on April 9th https://www.keystonesymposia.org/index.cfm?e=...ingid=1272.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals   finally had some luck with a troubled program. Clovis Oncology   took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Why Neuralstem Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem  a clinical-stage...
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
PR Newswire - Fri Mar 28, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the application of the cells for transplantation therapy in ischemic stroke. The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients
Equities Recording New Highs: Generac Holding, Sempra Energy, Neuralstem, and Great Plains Energy
PR Newswire - Tue Mar 18, 8:41AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Generac Holdings Inc. (NYSE:GNRC), Sempra Energy (NYSE:SRE), Neuralstem Inc. (NYSE MKT: CUR), and Great Plains Energy Inc. (NYSE:GXP). Free research on these four companies can be accessed at:
Why Neuralstem Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 12:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem , a clinical-stage...
Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
PR Newswire - Mon Mar 17, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full. In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes," results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial. These six patients were the first to receive cervical stem cell transplants. Three of them were also the first to be transplanted along the length of their spines, in both the lumbar and the cervical regions. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits. This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
4 Stocks Under $10 Moving Higher
at The Street - Wed Mar 12, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Neuralstem posts higher net loss of USD19.832m in 2013
M2 - Tue Mar 11, 4:24AM CDT
Biopharmaceutical company Neuralstem (NYSE MKT:CUR) on Monday reported its net loss of USD19.832m (USD0.27 per share) for the year ended 31 December 2013.
Neuralstem Announces 2013 Financial Results
PR Newswire - Mon Mar 10, 8:00AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Neuralstem, Inc. "Right to Try"
ACCESSWIRE - Mon Mar 03, 8:45AM CST
ACCESSWIRE / Mar 3, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) published a blog post on the Company's website (http://neuralstem.com/neuralstem-ceo-blog/208-every-man-gotta-right-to-decide-his-own-destiny) which was republished on TheChairmansBlog.com. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
CNP Assurances: 2013 Results
PR Newswire - Thu Feb 20, 1:49AM CST
Attributable net profit up 8.3% to EUR 1,030m in 2013
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014
PR Newswire - Thu Feb 06, 8:00AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual BIO CEO & Investor Conference 2014 in New York City on Tuesday, February 11, at 3:00 p.m. EST. Garr will present clinical updates on the company's 2014 NSI-566 cell therapy trials program, including ongoing ALS Phase II; ALS Phase II in Mexico City; FDA-approved chronic spinal cord injury Phase I; acute spinal cord injury Phase I in Seoul; and ischemic stroke Phase I/II, which commenced in December 2013 in Beijing.
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Neuralstem Inc names Catherine Angell Sohn to board
M2 - Wed Jan 15, 4:03AM CST
Neural stem cells company Neuralstem Inc (NYSE MKT:CUR) reported on Tuesday the addition of Dr Catherine Angell Sohn (Pharm.D.) to its board of directors.
Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
PR Newswire - Tue Jan 14, 8:00AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board members to six. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline, where she spearheaded global commercialization for this $8 billion division and led a series of international licensing deals. Earlier during her 28-year tenure at GlaxoSmithKline, Dr. Sohn established the U.S. Vaccine Business Unit, leading to the launch of the company's first vaccine in the U.S., which grew to more than $100 million in sales. She was also involved in the U.S. launch of the company's central nervous system (CNS) product, Paxil, which subsequently grew to more than $1 billion in sales.
Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference
PR Newswire - Mon Apr 07, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) will present Phase I data at the Keystone Symposia, "Engineering Cell Fate and Function," in Olympic Valley, California, on April 9th https://www.keystonesymposia.org/index.cfm?e=...ingid=1272.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals   finally had some luck with a troubled program. Clovis Oncology   took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Why Neuralstem Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 1:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem  a clinical-stage...
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
PR Newswire - Fri Mar 28, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the application of the cells for transplantation therapy in ischemic stroke. The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients
Equities Recording New Highs: Generac Holding, Sempra Energy, Neuralstem, and Great Plains Energy
PR Newswire - Tue Mar 18, 8:41AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Generac Holdings Inc. (NYSE:GNRC), Sempra Energy (NYSE:SRE), Neuralstem Inc. (NYSE MKT: CUR), and Great Plains Energy Inc. (NYSE:GXP). Free research on these four companies can be accessed at:
Why Neuralstem Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 12:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Neuralstem , a clinical-stage...
Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
PR Newswire - Mon Mar 17, 8:15AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full. In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes," results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial. These six patients were the first to receive cervical stem cell transplants. Three of them were also the first to be transplanted along the length of their spines, in both the lumbar and the cervical regions. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits. This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
4 Stocks Under $10 Moving Higher
at The Street - Wed Mar 12, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Neuralstem posts higher net loss of USD19.832m in 2013
M2 - Tue Mar 11, 4:24AM CDT
Biopharmaceutical company Neuralstem (NYSE MKT:CUR) on Monday reported its net loss of USD19.832m (USD0.27 per share) for the year ended 31 December 2013.
Neuralstem Announces 2013 Financial Results
PR Newswire - Mon Mar 10, 8:00AM CDT
Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Neuralstem, Inc. "Right to Try"
ACCESSWIRE - Mon Mar 03, 8:45AM CST
ACCESSWIRE / Mar 3, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) published a blog post on the Company's website (http://neuralstem.com/neuralstem-ceo-blog/208-every-man-gotta-right-to-decide-his-own-destiny) which was republished on TheChairmansBlog.com. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
CNP Assurances: 2013 Results
PR Newswire - Thu Feb 20, 1:49AM CST
Attributable net profit up 8.3% to EUR 1,030m in 2013
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014
PR Newswire - Thu Feb 06, 8:00AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual BIO CEO & Investor Conference 2014 in New York City on Tuesday, February 11, at 3:00 p.m. EST. Garr will present clinical updates on the company's 2014 NSI-566 cell therapy trials program, including ongoing ALS Phase II; ALS Phase II in Mexico City; FDA-approved chronic spinal cord injury Phase I; acute spinal cord injury Phase I in Seoul; and ischemic stroke Phase I/II, which commenced in December 2013 in Beijing.
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Neuralstem Inc names Catherine Angell Sohn to board
M2 - Wed Jan 15, 4:03AM CST
Neural stem cells company Neuralstem Inc (NYSE MKT:CUR) reported on Tuesday the addition of Dr Catherine Angell Sohn (Pharm.D.) to its board of directors.
Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
PR Newswire - Tue Jan 14, 8:00AM CST
Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board members to six. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline, where she spearheaded global commercialization for this $8 billion division and led a series of international licensing deals. Earlier during her 28-year tenure at GlaxoSmithKline, Dr. Sohn established the U.S. Vaccine Business Unit, leading to the launch of the company's first vaccine in the U.S., which grew to more than $100 million in sales. She was also involved in the U.S. launch of the company's central nervous system (CNS) product, Paxil, which subsequently grew to more than $1 billion in sales.
